Bayani-671, KEYTRUDA, Merck, Bayanin NSCLC, Pembrolizumab
Neoadjuvant/adjuvant pembrolizumab an amince da shi daga FDA don sake sake fasalin cutar kansar huhu mara ƙarami.
Nov 2023: Pembrolizumab (Keytruda, Merck) ya sami izini daga Hukumar Abinci da Magunguna (FDA) a matsayin maganin neoadjuvant a hade tare da chemotherapy mai ɗauke da platinum kuma azaman maganin adjuvant na bayan tiyata f..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv tare da pembrolizumab an amince da su daga USFDA don ci gaba na gida ko na ciwon daji na urothelial
Feb 2024: Hukumar Abinci da Magunguna ta haɓaka aiwatar da amincewar magunguna guda biyu, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) da pembrolizumab (Keytruda, Merck). Wadannan magungunan ana nufin su yi wa mutanen da ke cikin gida..
FDA, Abinci da Drug Administration, KEYTRUDA, Merck, Pembrolizumab, chemotherapy na tushen platinum
Pembrolizumab an amince da shi ta FDA a matsayin jiyya don ciwon huhu mara ƙarami
Feb 2023: Don mataki IB (T2a 4 cm), mataki na II, ko mataki IIIA ciwon huhu mara karami, Hukumar Abinci da Magunguna (FDA) ta amince da pembrolizumab (Keytruda, Merck) a matsayin maganin adjuvant bayan resection da platinum na tushen chemoth. ..
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Tsarin Kiwon Lafiya na Ventana
An amince da Pembrolizumab don ci gaba da ciwon daji na endometrial
Afrilu 2022: Hukumar Abinci da Magunguna ta amince da Pembrolizumab (Keytruda, Merck) a matsayin wakili ɗaya ga marasa lafiya da ke fama da ciwon daji na endometrial wanda ke da rashin zaman lafiya-high (MSI-H) ko gyara rashin daidaituwa.
NCT03142334, Pembrolizumab, renal cell carcinoma
An amince da Pembrolizumab don maganin ciwon daji na renal cell
Jan 2022: Hukumar Abinci da Magunguna ta amince da Pembrolizumab (Keytruda, Merck) don kula da marasa lafiya da ke fama da ciwon daji na renal cell (RCC) waɗanda ke tsaka-tsaki ko babban haɗarin sake dawowa bayan ..
Bevacizumab, KEYTRUDA, Merck, PD-L1, Pembrolizumab
Haɗin Pembrolizumab an amince da shi ta FDA don layin farko na maganin kansar mahaifa
Nov 2021: Pembrolizumab (Keytruda, Merck) tare da haɗin gwiwa tare da chemotherapy, tare da ko ba tare da bevacizumab ba, Hukumar Abinci da Magunguna ta amince da marasa lafiya da ke da ciwon sankarar mahaifa, maimaituwa, ko ƙazamin mahaifa.
KEYTRUDA, Merck, Pembrolizumab, TNBC
FDA ta amince da Pembrolizumab don babban haɗarin farkon cutar kansa sau uku
Agusta 2021: FDA ta amince da Pembrolizumab (Keytruda, Merck) don babban haɗari, farkon cutar kansa mai cutar kansa sau uku (TNBC) a matsayin magani neoadjuvant a haɗe tare da ilimin jiyya, kuma daga baya a matsayin wakili ɗaya azaman adjuv ..
Eisai, KEYTRUDA, Lenvatinib, Lenvima, Merck, NCT03517449, Pembrolizumab
FDA ta amince da Pembrolizumab da lenvatinib don ci gaba da ciwon daji na endometrial
Agusta 2021: Pembrolizumab (Keytruda, Merck) a hade tare da lenvatinib (Lenvima, Eisai) Hukumar Abinci da Magunguna ta amince da shi ga marasa lafiya da ciwon sankara na endometrial mai ci gaba wanda ba microsatellite instabi ..
fluoropyrimidine, Ciwon mahaifa (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co., Pembrolizumab, Trastuzumab
Pembrolizumab tana samun amincewar gaggawa daga FDA don cutar kansa ta ciki HER2
Agusta 2021: Pembrolizumab (Keytruda, Merck & Co.) a haɗe tare da trastuzumab, fluoropyrimidine-, da platinum-dauke da chemotherapy an ba da izini cikin hanzari ta Hukumar Abinci da Magunguna don firs.
cisplatin, carcinoma esophageal, fluorouracil, GEJ, Bayani-590, NCT03189719, Pembrolizumab
FDA ta amince da Pembrolizumab don maganin cutar mahaifa ko ciwon ciki
Agusta 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) a haɗe tare da platinum da fluoropyrimidine-tushen chemotherapy ya sami amincewar Hukumar Abinci da Magunguna ga marasa lafiya da keɓaɓɓu ko yanki.